The COVID-19 pandemic has brought many changes to the pharmaceutical industry, among them how companies can continue to engage with healthcare professionals (HCPs) and other stakeholders.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
